Experience
Intellia Therapeutics, Inc.
In connection with Intellia Therapeutics’s acquisition of biotechnology startup Rewrite Therapeutics, Inc., Intellia engaged Finnegan to assess intellectual property (IP) issues as part of the due diligence efforts. The deal was valued at $45 million and involved Rewrite’s IP assets focused on DNA writing via CRISPR. Rewrite is also entitled to receive up to $155 million in potential pre-specified research and regulatory approval milestones.
Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Acorda Therapeutics, Inc. v. Apotex Inc.
Acorda Therapeutics, Inc.
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
American Regent, Inc.
$45 million judgment overturned for Ericsson
Ericsson Inc.
Vacating a $110 million judgment against Finnegan client TCL Communication
TCL Communication Technology
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.